Cytek Biosciences (CTKB) EBT Margin (2020 - 2026)
Cytek Biosciences (CTKB) posted EBT Margin of 39.36% for Q1 2026, down 506.82% on a QoQ basis from 6.49% in Q4 2025, and down 1219.0% year-over-year from 3.52% in Q1 2025.
Cytek Biosciences (CTKB) EBT Margin (2020 - 2026) Analysis & Trends
Cytek Biosciences' EBT Margin history runs 7 years deep, the most recent figure standing at 39.36% for Q1 2026.
- Quarterly EBT Margin fell 1219.0% year-over-year to 39.36% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 17.61% (down 1356.0% YoY) and the FY2025 annual result came in at 14.81%, down 1197.0% from the prior year.
- EBT Margin was 39.36% for Q1 2026 at Cytek Biosciences, down from 6.49% in the prior quarter.
- Across five years, EBT Margin topped out at 17.96% in Q4 2024 and bottomed at 39.36% in Q1 2026.
- A 5-year average of 9.36% and a median of 9.42% in 2022 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2024 — EBT Margin surged 1090 bps — and 2025, when it tumbled 2445 bps.
- Cytek Biosciences' EBT Margin stood at 8.51% in 2022, then decreased by 17 bps to 7.06% in 2023, then surged by 154 bps to 17.96% in 2024, then sank by 136 bps to 6.49% in 2025, then plunged by 507 bps to 39.36% in 2026.
- Business Quant data shows CTKB's EBT Margin at 39.36% in Q1 2026, 6.49% in Q4 2025, and 14.86% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 12.98% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 14.12% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 18.70% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 22.33% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 27.84% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 22.61% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 4.87% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 9.84% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Cytek Biosciences | 586.89 Mn | 521.19 Mn | 21.25 Mn | -39.36% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -39.36% |
| Dec 31, 2025 | -6.49% |
| Sep 30, 2025 | -14.86% |
| Jun 30, 2025 | -14.86% |
| Mar 31, 2025 | -27.18% |
| Dec 31, 2024 | 17.96% |
| Sep 30, 2024 | 0.30% |
| Jun 30, 2024 | -15.41% |
| Mar 31, 2024 | -20.05% |
| Dec 31, 2023 | 7.06% |
| Sep 30, 2023 | -8.72% |
| Jun 30, 2023 | -13.27% |
| Mar 31, 2023 | -24.37% |
| Dec 31, 2022 | 8.51% |
| Sep 30, 2022 | 4.57% |
| Jun 30, 2022 | -3.49% |
| Mar 31, 2022 | -9.42% |
| Dec 31, 2021 | 1.14% |
| Sep 30, 2021 | 6.04% |
| Jun 30, 2021 | 10.74% |